ATRC
Neutral signalScored 2026-09-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
AtriCure, Inc.
- Nom
- AtriCure, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NASDAQ
- Capitalisation
- $3.0B
- Employés
- 1,350
- PDG
- Michael H. Carrel
- Site web
- https://www.atricure.com
- Marché
- ADGMBSXEWLIVNMDT
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 12 377 titres (~560 824,06 $ US)
- Insiders
- GROVES REGINA EPrange KarenYuen Maggie
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$3,317,897
Avg sell (VWAP, 90d window) $44.32 vs last close $55.14 (+24.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$879,832 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-11
- Liquidity
- Liquid $91,202,274/day · 20d vol
- Last synced
-
2026-10-02 21:10:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-23 | Privitera Salvatore | Sell · S · 10b5-1 | 4,519 | $60.00 | $271,140 | Form 4 |
| 2026-09-11 | GROVES REGINA E | Sell · S | 5,313 | $54.22 | $288,071 | Form 4 |
| 2026-09-08 | Privitera Salvatore | Sell · S · 10b5-1 | 3,657 | $55.00 | $201,135 | Form 4 |
| 2026-09-02 | Privitera Salvatore | Sell · S · 10b5-1 | 7,763 | $52.50 | $407,558 | Form 4 |
| 2026-08-24 | Dahlquist Karl S. | Sell · S | 9,370 | $48.89 | $458,099 | Form 4 |
| 2026-08-05 | Prange Karen | Sell · S | 3,564 | $38.80 | $138,283 | Form 4 |
| 2026-08-05 | Yuen Maggie | Sell · S | 3,500 | $38.42 | $134,470 | Form 4 |
| 2026-07-29 | Noznesky Justin J | Sell · S | 6,182 | $38.80 | $239,862 | Form 4 |
| 2026-07-28 | Doraiswamy Vinayak | Sell · S | 6,000 | $38.88 | $233,280 | Form 4 |
| 2026-07-28 | WEHRWEIN SVEN | Sell · S | 25,000 | $37.84 | $946,000 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-20 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-20 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-03 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-06 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-06 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2024-07-19 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-06-18 | Josh S. Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2021-06-08 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-04-30 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-03-31 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2020-02-21 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2019-11-07 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-06-27 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-05-08 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
ATRC presents a mixed picture: while liquidity is solid (85) and operational trends are improving, the weak catalyst score (35) driven by a modest congressional trade signal is heavily undermined by $560k+ in insider…
The first sentence of the analysis written for ATRC on 2026-09-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 3.96 · operating margin -0.6% — readings disagree
Suggested stop 45.37, nearest stored support minus 0.5 ATR(17.7% under the last close). Reward/risk to the next stored resistance is 0.67. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 74.4% | 74.7% | 75.2% | 74.4% | 75.0% | |
| Ebit Margin | -0.8% | -8.0% | -5.7% | -12.5% | 20.2% | |
| Ebitda Margin | 3.0% | -4.0% | -2.0% | -8.9% | 24.0% | |
| Operating Profit Margin | -0.6% | -8.6% | -6.7% | -12.9% | 20.1% | |
| Pretax Profit Margin | -1.9% | -9.4% | -7.5% | -14.0% | 18.4% | |
| Continuous Operations Profit Margin | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% | |
| Net Profit Margin | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% | |
| Bottom Line Profit Margin | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% | |
| Current Ratio | 3.956 | 3.648 | 3.570 | 3.686 | 3.474 | |
| Quick Ratio | 2.993 | 2.622 | 2.660 | 2.899 | 2.783 | |
| Solvency Ratio | 0.056 | -0.175 | -0.106 | -0.270 | 0.461 | |
| Cash Ratio | 2.054 | 1.671 | 1.131 | 0.995 | 0.773 | |
| Price To Earnings Ratio | -164.833 | -32.168 | -54.076 | -43.510 | 62.640 | |
| Price To Earnings Growth Ratio | 2.206 | -0.732 | 1.532 | 0.227 | -0.317 | |
| Forward Price To Earnings Growth Ratio | 2.206 | -0.732 | 1.532 | 0.227 | -0.317 | |
| Price To Earnings Diluted Ratio | -164.833 | -32.168 | -54.076 | -43.510 | 63.789 | |
| Price To Earnings Diluted Growth Ratio | 2.206 | -0.732 | 1.532 | 0.225 | -0.326 | |
| Price To Book Ratio | 3.840 | 3.114 | 3.545 | 4.444 | 6.477 | |
| Price To Sales Ratio | 3.534 | 3.085 | 4.140 | 6.144 | 11.422 | |
| Price To Free Cash Flow Ratio | 39.122 | -127.521 | -44.057 | -52.020 | -133.151 | |
| Price To Operating Cash Flow Ratio | 32.947 | 117.605 | 368.592 | -91.682 | -227.390 | |
| Debt To Assets Ratio | 0.135 | 0.126 | 0.121 | 0.127 | 0.123 | |
| Debt To Equity Ratio | 0.179 | 0.166 | 0.160 | 0.163 | 0.156 | |
| Debt To Capital Ratio | 0.152 | 0.142 | 0.138 | 0.140 | 0.135 | |
| Long Term Debt To Capital Ratio | 0.130 | 0.118 | 0.115 | 0.111 | 0.110 | |
| Financial Leverage Ratio | 1.330 | 1.322 | 1.317 | 1.282 | 1.272 | |
| Working Capital Turnover Ratio | 2.455 | 2.410 | 2.291 | 2.229 | 1.381 | |
| Operating Cash Flow Ratio | 0.703 | 0.166 | 0.060 | -0.379 | -0.244 | |
| Operating Cash Flow Sales Ratio | 0.107 | 0.026 | 0.011 | -0.067 | -0.050 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.842 | -0.922 | -8.366 | 1.762 | 1.708 | |
| Debt Service Coverage Ratio | 1.663 | -2.123 | -0.920 | -3.579 | 13.330 | |
| Interest Coverage Ratio | -0.586 | -6.245 | -3.853 | -8.558 | 11.225 | |
| Short Term Operating Cash Flow Coverage Ratio | 18.370 | 4.351 | 1.770 | -6.643 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.651 | 0.159 | 0.060 | -0.297 | -0.182 | |
| Capital Expenditure Coverage Ratio | 6.335 | 0.520 | 0.107 | -1.312 | -1.413 | |
| Dividend Paid And Capex Coverage Ratio | 6.335 | 0.520 | 0.107 | -1.312 | -1.413 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 111.386 | -74.947 | -202.608 | -69.364 | 48.146 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 74.4% | ▼-0.3% | ▼-0.4% |
| Ebit Margin | -0.8% | ▲7.2% | ▲0.6% |
| Ebitda Margin | 3.0% | ▲7.0% | ▲0.6% |
| Operating Profit Margin | -0.6% | ▲8.0% | ▲1.1% |
| Pretax Profit Margin | -1.9% | ▲7.5% | ▲1.0% |
| Continuous Operations Profit Margin | -2.1% | ▲7.5% | ▲0.9% |
| Net Profit Margin | -2.1% | ▲7.5% | ▲0.9% |
| Bottom Line Profit Margin | -2.1% | ▲7.5% | ▲0.9% |
| Current Ratio | 3.956 | ▲0.309 | ▲0.289 |
| Quick Ratio | 2.993 | ▲0.372 | ▲0.202 |
| Solvency Ratio | 0.056 | ▲0.231 | ▲0.063 |
| Cash Ratio | 2.054 | ▲0.382 | ▲0.729 |
| Price To Earnings Ratio | -164.833 | ▼-132.665 | ▼-118.444 |
| Price To Earnings Growth Ratio | 2.205 | ▲2.938 | ▲1.623 |
| Forward Price To Earnings Growth Ratio | 2.205 | ▲2.938 | ▲1.623 |
| Price To Earnings Diluted Ratio | -164.833 | ▼-132.665 | ▼-118.674 |
| Price To Earnings Diluted Growth Ratio | 2.205 | ▲2.938 | ▲1.625 |
| Price To Book Ratio | 3.840 | ▲0.726 | ▼-0.444 |
| Price To Sales Ratio | 3.534 | ▲0.449 | ▼-2.131 |
| Price To Free Cash Flow Ratio | 39.123 | ▲166.644 | ▲102.648 |
| Price To Operating Cash Flow Ratio | 32.947 | ▼-84.658 | ▼-7.067 |
| Debt To Assets Ratio | 0.135 | ▲0.009 | ▲0.008 |
| Debt To Equity Ratio | 0.179 | ▲0.013 | ▲0.014 |
| Debt To Capital Ratio | 0.152 | ▲0.009 | ▲0.010 |
| Long Term Debt To Capital Ratio | 0.130 | ▲0.011 | ▲0.013 |
| Financial Leverage Ratio | 1.330 | ▲0.008 | ▲0.025 |
| Working Capital Turnover Ratio | 2.455 | ▲0.045 | ▲0.302 |
| Operating Cash Flow Ratio | 0.703 | ▲0.537 | ▲0.642 |
| Operating Cash Flow Sales Ratio | 0.107 | ▲0.081 | ▲0.102 |
| Free Cash Flow Operating Cash Flow Ratio | 0.842 | ▲1.764 | ▲1.837 |
| Debt Service Coverage Ratio | 1.663 | ▲3.786 | ▼-0.012 |
| Interest Coverage Ratio | -0.586 | ▲5.659 | ▲1.017 |
| Short Term Operating Cash Flow Coverage Ratio | 18.370 | ▲14.020 | ▲14.801 |
| Operating Cash Flow Coverage Ratio | 0.651 | ▲0.492 | ▲0.573 |
| Capital Expenditure Coverage Ratio | 6.335 | ▲5.815 | ▲5.488 |
| Dividend Paid And Capex Coverage Ratio | 6.335 | ▲5.815 | ▲5.488 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 111.386 | ▲186.333 | ▲148.864 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.89B | $1.44B | $1.65B | $2.03B | $3.13B | |
| Enterprise value | $1.81B | $1.39B | $1.64B | $2.05B | $3.17B | |
| EV / Sales | 3.38x | 2.98x | 4.12x | 6.19x | 11.54x | |
| EV / Op. cash flow | 31.56x | 113.82x | 366.40x | -92.42x | -229.71x | |
| EV / Free cash flow | 37.48x | -123.42x | -43.80x | -52.44x | -134.51x | |
| EV / EBITDA | 111.39x | -74.95x | -202.61x | -69.36x | 48.15x | |
| Net debt / EBITDA | -4.89x | 2.49x | 1.21x | -0.56x | 0.49x | |
| Current ratio | 3.96x | 3.65x | 3.57x | 3.69x | 3.47x | |
| Income quality | -5.01x | -0.27x | -0.15x | 0.48x | -0.28x | |
| Graham number | — | — | — | — | $16 | |
| Graham net-net | $2 | $1 | $1 | $1 | $1 | |
| Tax burden | 112.6% | 102.3% | 102.0% | 100.6% | 99.6% | |
| Interest burden | 237.2% | 117.2% | 130.2% | 112.1% | 91.1% | |
| Working capital | $241.0M | $194.4M | $191.7M | $156.8M | $139.6M | |
| Invested capital | $569.8M | $533.0M | $537.2M | $473.6M | $453.6M | |
| Return on assets | -1.7% | -7.3% | -5.0% | -7.9% | 8.2% | |
| Operating ROA | -0.5% | -6.5% | -4.4% | -7.1% | 8.3% | |
| Return on tangible assets | -3.1% | -14.1% | -9.7% | -14.9% | 14.9% | |
| Return on equity | -2.3% | -9.7% | -6.5% | -10.2% | 10.4% | |
| Return on invested capital | -0.6% | -7.4% | -4.9% | -8.0% | 9.8% | |
| Return on capital employed | -0.6% | -7.5% | -4.9% | -8.1% | 9.9% | |
| Earnings yield | -0.6% | -3.1% | -1.8% | -2.3% | 1.6% | |
| Free cash flow yield | 2.6% | -0.8% | -2.3% | -1.9% | -0.8% | |
| Capex / Op. cash flow | 15.8% | 192.2% | 936.6% | -76.2% | -70.8% | |
| Capex / Depreciation | 44.1% | 125.2% | 283.5% | 144.2% | 93.4% | |
| Capex / Sales | 1.7% | 5.0% | 10.5% | 5.1% | 3.6% | |
| SG&A / Sales | 58.2% | 62.6% | 63.4% | 70.0% | 74.6% | |
| R&D / Sales | 16.9% | 20.7% | 18.5% | 17.4% | 17.7% | |
| Stock comp / Sales | 8.4% | 8.7% | 8.9% | 8.7% | 10.2% | |
| Intangibles / Total assets | 43.2% | 47.8% | 48.7% | 46.8% | 45.1% | |
| Days sales outstanding | 46d | 47d | 48d | 47d | 44d | |
| Days payables outstanding | 209d | 78d | 101d | 86d | 99d | |
| Operating cycle | 255d | 281d | 299d | 246d | 252d | |
| Cash conversion cycle | 46d | 203d | 198d | 160d | 153d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-14 Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year? Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
- 2026-09-12 AtriCure CTO Sells 3,657 Shares The transaction was valued at $201,000. The sale represented 2% of the insider''s direct equity holdings prior to the transaction.
- 2026-09-10 Do Options Traders Know Something About AtriCure Stock We Don''t? Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
- 2026-09-09 AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue? AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company''s fundamentals for clues.
- 2026-08-27 Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
- 2026-08-25 AtriCure to Participate in the 2026 Wells Fargo Health Care Conference MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure''s management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a.
- 2026-08-21 AtriCure: Promising Cardiovascular Surgical Platform AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we''ve already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.
- 2026-08-11 AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
- 2026-08-11 A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95 On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s
- 2026-08-07 Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here''s What Matters for Investors This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director''s total equity holdings by 20%, based on holdings reported in the Form 4.